In vitro activity of cefepime/zidebactam (WCK 5222) against Gram-negative bacteria

May 7, 2017 at 7:58 pm

Journal of Antimicrobial Chemotherapy May 2017 V.72 N.5

EDITOR’S CHOICE

David M. Livermore; Shazad Mushtaq; Marina Warner; Anna Vickers; Neil Woodford

Objectives:

Diazabicyclooctanes (DBOs) inhibit class A, class C and some class D β-lactamases. A few also bind PBP2, conferring direct antibacterial activity and a β-lactamase-independent ‘enhancer’ effect, potentiating β-lactams targeting PBP3. We tested a novel DBO, zidebactam, combined with cefepime.

Methods:

CLSI agar dilution MICs were determined with cefepime/zidebactam in a chequerboard format. Bactericidal activity was also measured.

Results:

Zidebactam MICs were ≤2 mg/L (mostly 0.12–0.5 mg/L) for most Escherichia coli, Klebsiella, Citrobacter and Enterobacter spp., but were >32 mg/L for Proteeae, most Serratia and a few E. coli, Klebsiella and Enterobacter/Citrobacter. The antibacterial activity of zidebactam dominated chequerboard studies for Enterobacteriaceae, but potentiation of cefepime was apparent for zidebactam-resistant isolates with class A and C enzymes, illustrating β-lactamase inhibition. Overall, cefepime/zidebactam inhibited almost all Enterobacteriaceae with AmpC, ESBL, K1, KPC and OXA-48-like β-lactamases at 1 + 1 mg/L and also 29 of 35 isolates with metallo-carbapenemases, including several resistant to zidebactam alone. Zidebactam MICs for 36 of 50 Pseudomonas aeruginosa were 4–16 mg/L, and the majority of AmpC, metallo-β-lactamase-producing and cystic fibrosis isolates were susceptible to cefepime/zidebactam at 8 + 8 mg/L. Zidebactam MICs for Acinetobacter baumannii and Stenotrophomonas maltophilia were >32 mg/L; potentiation of cefepime was frequent for S. maltophilia, but minimal for A. baumannii. Kill curve results largely supported MICs.

Conclusions:

Zidebactam represents a second triple-action DBO following RG6080, with lower MICs for Enterobacteriaceae and P. aeruginosa. Clinical evaluation of cefepime/zidebactam must critically evaluate the reliance that can be placed on this direct antibacterial activity and on the enhancer effect as well as β-lactamase inhibition.

PDF

https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/jac/72/5/10.1093_jac_dkw593/1/dkw593.pdf?Expires=1494290748&Signature=LS~WEfmC9yA22ZLeOO5MTEq-ovySpA8AANP0PAy9zm08YHIwrxp8VusV4iNC1RrwaCWsl5l3jHVkhY9q1Fihfm9uoMoVGno7tlEQeBvNriPMi8KQ~lqtQ0hkuMVKEs5j7CHcSJMHLTrK7DOIcJq9ZkhKUVg32kF8So6ywsULYbCoIk~iQ0cPTM5Ic2iHso5T6-c82mCP8R~5gaAMy4KFRSuhgEYLhlY~lPXt8I3d89UukOF4eg2sFGzVRlmSv7CNLRul~d4Z2cMrwyHJ6FcqE5MdcMq0Jv6oEq6NMMBVAwNl8DzrOdd9DOkPnVhgJhkYvuqvf6z-2tmZrWptHyHjcw__&Key-Pair-Id=APKAIUCZBIA4LVPAVW3Q

 

Advertisements

Entry filed under: Antimicrobianos, Bacterias, Metodos diagnosticos, Resistencia bacteriana, Sepsis, Update.

REVIEW – DNA replication proteins as potential targets for antimicrobials in drug-resistant bacterial pathogens Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing urinary tract and intraabdominal infections in Europe: report from an antimicrobial surveillance programme (2012–15)


Calendar

May 2017
M T W T F S S
« Apr   Jun »
1234567
891011121314
15161718192021
22232425262728
293031  

Most Recent Posts


%d bloggers like this: